

HTANGEL

KEEPING YOU UP-TO-DATE ON
INTERNATIONAL HTA DECISIONS

Issue 23: March 2025

Very low approval rate in March!

This newsletter summarises final decisions from HTA bodies around the world from published reports in March 2025.

Good news for: **Ciltacabtagene autoleucel**, approved for relapsed and refractory multiple myeloma in Germany; **Lisocabtagene maraleucel**, approved for relapsed or refractory large B-cell lymphoma in England; and **Vedolizumab**, approved for moderate to severe Crohn's disease in Brazil.

Mixed news for: **Atezolizumab**, which was approved under special conditions for advanced NSCLC in Germany but not approved in England or Scotland; **Blinatumomab**, which was approved under special conditions for acute lymphoblastic leukaemia in England but not approved in Brazil; and **Dupilumab**, which was approved under special conditions for COPD but not approved for eosinophilic esophagitis in Germany.

Bad news for: **Crovalimab**, not approved for paroxysmal nocturnal haemoglobinuria in Germany; **Marstacimab**, not approved for routine prevention of bleeding in severe haemophilia in France; and **Zolbetuximab**, not approved for untreated, unresectable, advanced gastric or gastro-oesophageal junction adenocarcinoma in England.

“

16 Approvals

7 with special arrangements
1 with orphan drug status

“

40 Not approved

2 Excluded

1 Terminated

“

7 Evidence reviews

HTANGEL

Issue 23: March 2025

Pharmacological Technologies



Germany
IQWiG A25-12

Blood
Paroxymal nocturnal
haemoglobinuria
CROVALIMAB



Germany
IQWiG A24-94

Blood
Paroxymal nocturnal
haemoglobinuria
CROVALIMAB



France
HAS AP444

Blood
Haemophilia A,
Haemophilia B
MARSTACIMAB



France
HAS AP446

Cancer
Lymphoma
ACALABRUTINIB



Scotland
SMC2768

Cancer
Lung cancer
AMIVANTAMAB



England
NICE TA1047

Cancer
Lung cancer
ATEZOLIZUMAB



Germany
IQWiG A25-25

Cancer
Lung cancer
ATEZOLIZUMAB



Germany
IQWiG A24-97

Cancer
Lung cancer
ATEZOLIZUMAB



HTANGEL

Issue 23: March 2025

Pharmacological Technologies



Scotland
SMC2769

Cancer
Lung cancer
ATEZOLIZUMAB



Brazil
CONITEC

Cancer
Lung cancer
BRIGATINIB, LORLATINIB
AND ALECTINIBE



England
NICE TA1049

Cancer
Leukaemia
BLINATUMOMAB



Scotland
SMC2754

Cancer
Hepatocellular carcinoma
CABOZANTINIB



Brazil
CONITEC

Cancer
Leukaemia
BLINATUMOMAB



Germany
IQWiG A24-116

Cancer
Multiple myeloma
CILTACABTAGENE
AUTOLEUCEL



Brazil
CONITEC

Cancer
Leukaemia
BLINATUMOMAB



Germany
IQWiG A24-114

Cancer
Multiple myeloma
DARATUMUMAB



HTANGEL

Issue 23: March 2025

Pharmacological Technologies



England
NICE TA1048

Cancer
Lymphoma
LISOCABTAGENE
MARALEUCEL



Germany
IQWiG G24-36

Cancer
Ovarian cancer
MIRVETUXIMAB-
SORAVTANSINE



Wales
AWTTC 3317

Cancer
Colorectal cancer
NIVOLUMAB



Brazil
CONITEC

Cancer
Stomach cancer,
Gastroesophageal junction
cancer
NIVOLUMAB



Brazil
CONITEC

Cancer
Stomach cancer,
Gastroesophageal junction
cancer
RAMUCIRUMAB



Germany
IQWiG A24-124

Cancer
Breast cancer
RIBOCICLIB



Scotland
SMC2722

Cancer
Gastrointestinal
stromal cancer
RIPRETINIB



Scotland
SMC2753

Cancer
Prostate cancer
TALAZOPARIB



Pharmacological Technologies



Brazil
CONITEC

Cancer

**Stomach cancer,
Gastroesophageal junction
cancer**

TRASTUZUMAB



Approved



France
HAS AP437

Cancer

Breast cancer

**TRASTUZUMAB
DERUXTECAN**



**Not
approved**



Brazil
CONITEC

Cancer

Lung cancer

**TYROSINE KINASE
INHIBITORS**



**Not
approved**



England
NICE TA1046

Cancer

**Stomach cancer,
Gastroesophageal junction
cancer**

ZOLBETUXIMAB



**Not
approved**



Germany
IQWiG A24-113

Cardiovascular

**Eosinophilic
granulomatosis**

BENRALIZUMAB



**Not
approved**



Brazil
CONITEC

Cardiovascular

Heart failure

DAPAGLIFLOZIN



**Not
approved**



Germany
IQWiG A25-14

Cardiovascular

**Pulmonary
hypertension**

SOTATERCEPT



**Not
approved**



Germany
IQWiG A24-96

Cardiovascular

**Pulmonary
hypertension**

SOTATERCEPT



**Not
approved**

Pharmacological Technologies



Germany
IQWiG A24-117

Gastrointestinal
Eosinophilic
esophagitis
DUPIUMAB

X Not
approved



Germany
IQWiG A24-123

Genitourinary
Endometriosis
LINZAGOLIX

X Not
approved



Brazil
CONITEC

Gastrointestinal
Crohn's disease
VEDOLIZUMAB

✓ Approved



Brazil
CONITEC

Genitourinary
Endometriosis
ORAL
PROGESTOGENS

X Not
approved



Brazil
CONITEC

Genetic & Metabolic
Hereditary
angioedema
LANADELUMAB

X Not
approved



Brazil
CONITEC

Infection
Pneumococcal
disease
15-VALENT PNEUMOCOCCAL
CONJUGATE VACCINE

X Not
approved



Brazil
CONITEC

Genitourinary
Endometriosis
LEVONORGESTREL-
RELEASING INTRAUTERINE
DEVICE

X Not
approved



Brazil
CONITEC

Infection
Malaria
TAFENOQUINE

X Not
approved

HTANGEL

Issue 23: March 2025

Pharmacological Technologies



Wales
AWTTC 5306

Neurology
Multiple sclerosis
CLADRIBINE



Excluded



England
NICE TA1050

Neurology
Lennox-Gastaut syndrome
FENFLURAMINE



Approved
with special conditions



Brazil
CONITEC

Neurology
Alzheimer's disease
MEMANTINE
HYDROCHLORIDE



Not approved



Brazil
CONITEC

Neurology
Neuromyelitis optica spectrum disorder
SATRALIZUMAB



Not approved



Canada
CDA RD0071

Other
Migraine
CALCITONIN GENE-RELATED PEPTIDE INHIBITORS



Not approved



Brazil
CONITEC

Pregnancy
Contraception
ETONOGESTREL SUBDERMAL IMPLANT



Not approved



Brazil
CONITEC

Renal
Haemolytic uraemic syndrome
RAVULIZUMAB



Not approved



Brazil
CONITEC

Renal
Hyperkalaemia
SODIUM ZIRCONIUM CYCLOSILICATE



Approved



Pharmacological Technologies



England
NICE TA1045

Respiratory
Allergic rhinitis,
Allergic asthma
12 SQ-HDM SLIT

 **Approved**



Germany
IQWiG A24-79

Respiratory
Chronic obstructive
pulmonary disease
DUPILUMAB

 **Not
approved**



Germany
IQWiG A24-118

Respiratory
Chronic obstructive
pulmonary disease
DUPILUMAB

 **Approved
with special
conditions**



Scotland
SMC2729

Skin
Psoriasis
SPESOLIMAB

 **Not
approved**

Non-pharmacological Technologies



England
NICE IPG801

**Cardiovascular
Hypertension**

ALCOHOL-MEDIATED
PERIVASCULAR RENAL
SYMPATHETIC DENERVATION

 Not
approved



Argentina
IECS

Cardiovascular

Aortic dissection,
Aneurysm

CUSTOMIZED AORTIC
ENDOPROSTHESIS

 Not
approved



Argentina
IECS

Cardiovascular

Aortic dissection,
Aneurysm

CUSTOMIZED AORTIC
ENDOPROSTHESIS

 Not
approved



Korea
NECA HTA-2025-9

Musculoskeletal

Back pain

BASILAR NERVE
RADIOFREQUENCY
ABLATION

 Not
approved

Diagnostic Testing



Korea
NECA HTA-2025-10

Infection
COVID-19
SARS-COV-2
ANTIGEN TEST

Not
approved



Korea
NECA Innovation-
2025-1

Other
Diagnostic imaging
AI-BASED ABNORMALITY
DIAGNOSIS ASSISTANCE

Approved



Korea
NECA Innovation-
2025-2

Other
Diagnostic imaging
AI-BASED URINARY STONE
DIAGNOSIS ASSISTANCE

Approved

Other Guidance



Spain
OSTEBA

Cancer

Pancreatic cancer

**MAGNETIC NANOPARTICLES
AND A MAGNETIC FIELD
GENERATOR**



**Evidence
review**



Canada
CDA HE0048

Infection

COVID-19

**NIRMATRELVIR-
RITONAVIR**



**Evidence
review**



Canada
CDA HE0049

Infection

COVID-19

REMDESIVIR



**Evidence
review**



Canada
CDA HE0050

Infection

COVID-19

REMDESIVIR



**Evidence
review**



Canada
CDA HE0051

Infection

COVID-19

TOCILIZUMAB



**Evidence
review**



Canada
CDA HC0081

Other

Migraine

**CALCITONIN GENE-RELATED
PEPTIDE INHIBITORS**



**Evidence
review**



Canada
CDA CM0024

Other

Diagnostics

**COMPARATIVE EFFECTIVENESS
OF REAL-TIME TELEULTRASOUND
VERSUS IN-PERSON
ULTRASOUND**




**Evidence
review**

HTANGEL

Issue 23: March 2025

Further Information

HTAngel is designed to help keep you up to date with the latest HTA decisions around the world. Below is a breakdown of the tiles in the newsletter.



At Crystallise we aim to provide an innovative approach to processing information, using software tools to automate processes that are slower and less accurate when done by humans. Our approach provides clients with greater transparency and scope than they could find for the same budget elsewhere. We work with a network of experts and organisations that help us support clients efficiently and effectively, and are proud of our flexible and ingenious way of solving their problems.

For further information about HTAngel contact
newsletter@crystallise.com

To speak to us about our services contact
contact@crystallise.com